Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®

CNS Neuroscience and Therapeutics

Volumn 25, Issue 2, 2019, Pages 288-298

  Kandiah, Nagaendran ^a   Ong, Paulus Anam ^b   Yuda, Turana ^c   Ng, Li Ling ^d   Mamun, Kaysar ^e   Merchant, Reshma Aziz ^f   Chen, Christopher ^f   Dominguez, Jacqueline ^g   Marasigan, Simeon ^h   Ampil, Encarnita ^h   Nguyen, Van Thong ⁱ   Yusoff, Suraya ^j   Chan, Yee Fai ^k   Yong, Fee Mann ^l   Krairit, Orapitchaya ^m   Suthisisang, Chuthamanee ⁿ   Senanarong, Vorapun ^o   Ji, Yong ^p   Thukral, Ramesh ^q   Ihl, Ralf ^r  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b Hasan Sadikin Hospital   (Indonesia)

^c ATMA JAYA CATHOLIC UNIVERSITY OF INDONESIA   (Indonesia)

^d CHANGI GENERAL HOSPITAL   (Singapore)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g ST LUKE S MEDICAL CENTER   (Philippines)

^h UNIVERSITY OF SANTO TOMAS   (Philippines)

ⁱ CAN THO UNIVERSITY OF MEDICINE AND PHARMACY   (Viet Nam)

^j Sultan Ismail Hospital   (Malaysia)

^k HOSPITAL KUALA LUMPUR   (Malaysia)

^l SUBANG JAYA MEDICAL CENTRE   (Malaysia)

^m MAHIDOL UNIVERSITY   (Thailand)

ⁿ MAHIDOL UNIVERSITY   (Thailand)

^o MAHIDOL UNIVERSITY   (Thailand)

^p CAPITAL MEDICAL UNIVERSITY   (China)

^q Sahara Hospital   (India)

^r Krankenhaus Maria Hilf   (Germany)

more..

Author keywords

Alzheimer disease; cerebrovascular disease; dementia; EGb 761 ; Ginkgo biloba

Indexed keywords

CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; PLANT EXTRACT;

ADD ON THERAPY; ALZHEIMER DISEASE; ARTICLE; ASIA; BEHAVIOR; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COGNITION; COMORBIDITY; CONSENSUS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; MULTIINFARCT DEMENTIA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; COGNITIVE DEFECT; COMPLICATION; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CEREBROVASCULAR DISORDERS; COGNITIVE DYSFUNCTION; CONSENSUS; DEMENTIA; HUMANS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85060064520     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.13095     Document Type: Article

References (69)

1. Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209-215
2. Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:421-442
3. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M.World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer’s Disease International (ADI), 2015
4. Alzheimer's Disease International. World Alzheimer Report 2018. The state of the art of dementia research: New Fronteirs. September 2018. Available at: https://www.alz.co.uk/research/world-report-2018. Accessed Access date
5. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405-1412
6. Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7:80-93
7. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812-826
8. Catindig JA, Venketasubramanian N, Ikram MK, Chen C. Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors. J Neurol Sci. 2012;321:11-16
9. Chen C, Homma A, Mok VC, et al. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. J Intern Med. 2016;280:359-374
10. Kandiah N, Chander RJ, Ng A, Wen MC, Cenina AR, Assam PN. Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease. Eur J Neurol. 2015;22:150-155
11. Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:469-474
12. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279
13. Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC. Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort. Neurology. 2013;80:2112-2120
14. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262-1270
15. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269
16. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-1483
17. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73
18. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204
19. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999;354:919-920
20. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171-186
21. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer's and vascular types. Biomed Res Int. 2014;2014:908915
22. Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002;50:1431-1438
23. Chui HC, Ramirez-Gomez L. Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther. 2015;7:21
24. Prasad K, Wiryasaputra L, Ng A, Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. Dement Geriatr Cogn Disord. 2011;31:431-434
25. Kandiah N, Chander R, Zhang A, Yee CC. Cerebral white matter disease is independently associated with BPSD in Alzheimer's disease. J Neurol Sci. 2014;337:162-166
26. Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimers disease: is there any evidence? Curr Alzheimer Res. 2007;4(3):253-262
27. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997;278:1327-1332
28. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010;10:14
29. Ihl R, Bachinskaya N, Korczyn AD, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26:1186-1194
30. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46:716-723
31. Napryeyenko O, Borzenko I, Group G-NS. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57:4-11
32. Hoyer S, Lannert H, Noldner M, Chatterjee SS. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm (Vienna). 1999;106:1171-1188
33. Wu Y, Wu Z, Butko P, et al. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006;26:13102-13113
34. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci. 2000;12:1882-1890
35. Koltringer P, Langsteger W, Eber O. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761®. Clinical Hemorheology. 1995;15:649-656
36. Eckert A, Keil U, Kressmann S, et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry. 2003;36(Suppl 1):S15-23
37. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol. 2010;159:659-668
38. Huang SY, Jeng C, Kao SC, Yu JJ, Liu DZ. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr. 2004;23:615-621
39. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002;99:12197-12202
40. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31:490-502
41. Rodriguez M, Ringstad L, Schafer P, et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis. 2007;192:438-444
42. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29:47-56
43. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55:1409-1415
44. Gavrilova SI, Preuss UW, Wong JW, et al. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry. 2014;29:1087-1095
45. Zhao MX, Dong ZH, Yu ZH, Xiao SY, Li YM. [Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: a randomized controlled trial]. Zhong Xi Yi Jie He Xue Bao. 2012;10:628-634
46. ® in very mild cognitive impairment (vMCI). Neuroscience Med. 2011;2:48-56
47. Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761(R) in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065-2077
48. Hashiguchi M, Ohta Y, Shimizu M, Maruyama J, Mochizuki M. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. J Pharm Health Care Sci. 2015;1:14
49. von Gunten A, Schlaefke S, Uberla K. Efficacy of Ginkgo biloba extract EGb 761((R)) in dementia with behavioural and psychological symptoms: A systematic review. World J Biol Psychiatry. 2016;17:622-633
50. Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Treatment effects of Ginkgo biloba extract EGb 761(R) on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. Int Psychogeriatr. 2018;30:285-293
51. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11:851-859
52. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253-2262
53. Scherrer B, Andrieu S, Ousset PJ, et al. Analysing time to event data in dementia prevention trials: the example of the GuidAge study of EGb761. J Nutr Health Aging. 2015;19:1009-1011
54. Schulz M, Hoerr R, Mueller H. Ginkgo biloba extract EGb 761: A meta-analysis of adverse event rates from randomized, placebo-controlled, double-blind clinical trials. 46th ESCP Symposium on Clinical Pharmacy. 2017. Abstract PT051
55. Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. 2009;13:183-190
56. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. 2005;12:10-16
57. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis. 2007;18:787-793
58. BalDitSollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25:251-253
59. Halil M, Cankurtaran M, Yavuz BB, et al. No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment. Blood Coagul Fibrinolysis. 2005;16:349-353
60. Kohler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303-309
61. Guinot P, Caffrey E, Lambe R, Darragh A. Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. Haemostasis. 1989;19:219-223
62. Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs R D. 2006;7:163-172
63. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59:425-432
64. Ihl R, Bunevicius R, Frolich L, et al. World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. Int J Psychiatry Clin Pract. 2015;19:2-7
65. Ihl R, Frolich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry. 2011;12:2-32
66. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944
67. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260
68. Nacu A, Hoerr R. Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EG b 761® treatment: additional results from a 24-week randomized, placebo-controlled trial. Open Access Journal of Clinical Trials. 2016;8
69. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005;2:541-551